Business Wire

Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress


The Janssen Pharmaceutical Companies of Johnson & Johnson today announced multiple data presentations from its oncology portfolio and pipeline, including key data in lung cancer and bladder cancer, will be featured as part of the European Society for Medical Oncology (ESMO) Virtual Congress 2020, Science Weekend taking place 19–21 September.

Thirteen abstracts featuring Janssen data have been selected for presentation during the virtual congress, including an oral presentation and live Q&A of the latest data from the Phase 1 dose escalation study investigating amivantamab (JNJ-61186372) in combination with lazertinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC); updates on multiple Phase 1/2 studies evaluating erdafitinib in the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC); an update on patient-reported outcomes on health-related quality of life data from the final analysis of the Phase 3 SPARTAN study of apalutamide in patients with non-metastatic castration resistant prostate cancer (nmCRPC) with over four years of follow up. The full final analysis of the SPARTAN study was also recently published in European Urology.1 In addition, Janssen makes its first presentation of in-human data for early-stage investigational protein arginine methyltransferase 5 (PRMT5) inhibitor JNJ-9178 in multiple tumour models (relapsed/refractory B cell non-Hodgkin lymphoma or advanced solid tumours, including patients with lower risk myelodysplastic syndromes). 2,3

“Janssen’s data at this year’s congress demonstrates our continued commitment to advancing our broad oncology portfolio, driven by the critical unmet needs in solid tumours for some of the most prevalent cancers in Europe,” said Dr Joaquín Casariego, M.D., Janssen Therapeutic Area Lead, Oncology for Europe, Middle East & Africa, Janssen-Cilag, S.A. “The advancement of new approaches to cancer treatment and interception at earlier stages of the disease is vital to improve clinical outcomes and ultimately enhancing the quality of life for those affected by an oncologic diagnosis.”

Company-sponsored abstracts to be presented at the meeting include:

Abstract/Presentation No.



Proffered Paper 1: NSCLC Metastatic

Sunday 20th September

14:37–14:49 CET

Abstract #1258O

Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

On-Demand E-Poster Display Session

Thursday 17th September

Abstract #1405P

Survival of patients with Non-Small Lung Cancer and Exon 20 insertion mutation from the Czech Republic


On-Demand Mini Oral Session: Development Therapeutics

Friday 18th September

Abstract #537MO

First-in-Human Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 (PRMT5) inhibitor, in Patients with Advanced Cancers


On-Demand E-Poster Display Session

Thursday 17th September

Abstract #603TiP

Phase 2, Open-Label Study of Erdafitinib in Adult and Adolescent Patients with Advanced Solid Tumors Harboring Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

Abstract #750P

Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (mUC): Subgroup Analyses of Long-Term Efficacy Outcomes of a Pivotal Phase 2 Trial (BLC2001)

Abstract #751P

Analysis of Circulating Tumor DNA (ctDNA) From the Phase 2 BLC2001 Trial of Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma (mUC) to Identify Markers of Intrinsic Resistance to Fibroblast Growth Factor Receptor (FGFR)-Targeted Therapy

Abstract #752P

Updated Data From the NORSE Trial of Erdafitinib Plus Cetrelimab in Patients with Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Specific Fibroblast Growth Factor Receptor (FGFR) Alterations

Abstract #757P

An Observational Study of Outcomes of Patients with Advanced Urothelial Carcinoma (UC) After Anti-programmed Death-(Ligand) 1 (PD-[L]1) Therapy by Fibroblast Growth Factor Receptor Gene Alteration (FGFRa) Status

Abstract #758P

Assessment of Prognostic and Predictive Value of FGFR Alterations (FGFRa) in a Real-World Cohort of Patients with High-Risk pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC)


On-Demand E-Poster Display Session

Thursday 17th September

Abstract #632P

Health-Related Quality of Life (HRQoL) at Final Analysis of the SPARTAN Study of Apalutamide vs Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Receiving Androgen Deprivation Therapy (ADT)

Abstract #630P

Apalutamide for Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC): A Comparison of Real-Life Experience From an International Named Patient Program vs the Prior Phase 3 Clinical Study


On-Demand E-Poster Display Session

Thursday 17th September

Abstract #689TiP

NRG Oncology’s GU007 (NADIR) TiP: A Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy in High-Risk Prostate Cancer (With Initial Phase I)

Big Data and Artificial Intelligence Research

On-Demand E-Poster Display Session

Thursday 17th September

Abstract #695TiP

ORACULUM: A Retrospective Observational Epidemiological Study Using Artificial Intelligence and Natural Language Processing in Electronic Health Records to Characterize the Prostate Cancer pathway, Management and Outcomes in Europe, Middle East and Africa (EMEA region)

# #END# #

About apalutamide
Apalutamide is an orally administered, selective androgen receptor (AR) inhibitor approved in Europe and is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease and in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), also known as metastatic castration-sensitive prostate cancer (mCSPC), in combination with androgen deprivation therapy (ADT).4 In the U.S. apalutamide is also indicated for the treatment of nmCRPC and mCSPC.5

About erdafitinib
Erdafitinib is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor that is being studied in patients with selected FGFR gene alterations in locally advanced or metastatic urothelial cancer, in Bacillus Calmette-Guérin (BCG) experienced, high risk non-muscle-invasive bladder cancer and in advanced solid tumours.6,7,8,9,10,11 In 2019 erdafitinib was approved in the U.S. for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) that has susceptible FGFR3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.12 In 2008, Janssen Pharmaceutica N.V. entered into an exclusive worldwide license and collaboration agreement with Astex Pharmaceuticals to develop and commercialise erdafitinib.13

About amivantamab
Amivantamab (JNJ-6372) is an investigational EGFR-MET bispecific antibody with immune cell-directing activity, which targets activating and resistance EGFR mutations, and MET pathway activation.14,15 The production and development of the antibody followed Janssen Biotech, Inc.’s licensing agreement with Genmab for use of its DuoBody® technology platform.16

About lazertinib
Lazertinibi is an oral, third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity.17 It is currently being explored in combination with amivantamab in patients with advanced non-small cell lung cancer.18

About JNJ-9178
JNJ-64619178 is an oral, selective protein arginine methyltransferase 5 inhibitor which is currently being investigated in a Phase 1 study for the treatment of patients with relapsed/refractory B cell non-Hodgkin lymphoma or advanced solid tumours, including patients with lower risk myelodysplastic syndromes.3,19

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at Follow us at for our latest news. Janssen-Cilag S.A., Janssen Biotech, Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding potential benefits and further benefits of apalutamide, erdafitinib and amivantamab and JNJ-9178. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

i In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.

1 Smith, MR. et al. Apalutamide and Overall Survival in Prostate Cancer. Available at: Last accessed September 2020.

2 Suurs, F. et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 201 (2019) 103–119.

3 A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS. Available at: Last accessed September 2020.

4 European Medicines Agency. ERLEADA. Available at: Last accessed September 2020.

5 ERLEADA product information Available at: Last accessed September 2020.

6 U.S. National Library of Medicine. A study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor (FGFR) gene aberrations. Available at: Last accessed September 2020.

7 Loriot, Y. et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019; 381: 338–348.

8 A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations. Available at: Last accessed September 2020.

9 A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC). Available at: Last accessed September 2020.

10 A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer. Available at: Last accessed September 2020.

11 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. Available at: Last accessed September 2020.

12 U.S. Food and Drug Administration. BALVERSA Prescribing Information. Available at: Last accessed September 2020.

13 Astex. Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. Available at: Last accessed September 2020.

14 Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer. Available at: Last accessed September 2020.

15 Johnson & Johnson. Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations. Available at: Last accessed September 2020.

16 Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform. Available at: Last accessed September 2020.

17 Lazertinib. Available at: Last accessed September 2020.

18 A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Participants With Advanced Non-small Cell Lung Cancer. Available at: Last accessed September 2020.

19 Miller, HJ. et al. In vivo efficacy and pharmacodynamic modulation of JNJ-64619178, a selective PRMT5 inhibitor, in human lung and hematologic preclinical models. Cancer Res. 2019;79(13 Suppl):Abstract nr 950.

Job number: CP-176935

Contact information

Media Contacts:
Alexandra Nisipeanu
Mobile: +40 744 383 413

Noah Reymond
Mobile: +31 621 385 718

Investor Relations:
Christopher DelOrefice
Office: +1 732 524 2955

Jennifer McIntyre
Office: +1 732 524 3922

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Call of Duty: Mobile World Championship Tournament Is Back – More Than $2 Million in Prizes Up For Grabs!14.4.2021 18:30:00 CEST | Press release

Activision today announced the return of the Call of Duty®: MobileWorld Championship. Presented by Sony, and starting June 3, 2021, eligible players in Call of Duty: Mobile Ranked Mode can compete for in-game rewards and a share of the more than $2 million (USD) total prize pool. “The momentum worldwide for Call of Duty: Mobile is incredible as our players continue to have a great time playing,” said Matt Lewis, vice president, mobile at Activision. “Picking up from last year’s competition, we’ve increased the prize money up for grabs and number of teams that can qualify, so there are even more reasons for fans to prove they’ve got what it takes to be the best.” The Call of Duty: Mobile World Championship 2021 Presented by Sony is open to eligible entrants across the world and will be conducted regionally in multiple stages. Sony’s newest flagship smartphone, Xperia 1 III, will be the official mobile device of the World Championship and will provide an 120FPS gaming experience*. Eligib

Verimatrix Chief Revenue Officer To Speak at StreamTV Sports Summit14.4.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Lu Bolden, Chief Revenue Officer, will participate in a virtual panel discussion from 1-1:45 p.m. Eastern Time on Monday, April 19 during the StreamTV Sports Summit. Titled, “Playing Defense – The Fight Against Piracy,” the five-person panel will share their experiences surrounding the need for media organizations and rights holders to protect expensive sports rights agreements. They’ll also discuss to what extent it’s possible to prevent footage from being shared and distributed on social platforms. Additionally, the panel will provide the latest insights regarding the actual anti-piracy tools and techniques organizations turn to for help. Alongside Bolden, the panel participants include: Tony Maroulis, Principal Analyst, Ampere Analysis (panel moderator) Mark Barron, Principal Solutions Engineer, Akamai William Mao, Vice President,

Valbiotis Launches a Capital Increase Through a Private Placement14.4.2021 17:40:00 CEST | Press release

Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announces the launch of a capital increase within the context of a private placement through an accelerated bookbuilding process for an amount of approximately 12 million euros. This capital increase, with the removal of shareholders’ preferential subscription rights in favor of a category of persons, will be reserved exclusively for qualified investors as referred to in article 2(e) of Regulation (EU) 2017/1129 of June 14, 2017. Reasons for the offer The net proceeds of the capital increase are intended primarily to finance the acceleration of the development of TOTUM•854 (prevention of arterial hypertension) with the launch of three clinical trials at the end of this year including a Phase II/III clinical trial, prior to a health claim application. In partnership with a major healt

Lenovo Outlines Company Transformation Strategy - From Devices To Solutions Company14.4.2021 17:00:00 CEST | Press release

Today, during its annual global employee kickoff event broadcast to 63,000 employees, Lenovo unveiled its plans to drive transformation from a global devices company to a technology leader in global devices + solutions, services, and software. Lenovo CEO Yang Yuanqing and other executive leaders outlined the company’s strategy, structure, and goals that will fuel Lenovo’s next decade of growth and position it as one of the world’s most trusted and iconic technology leaders, delivering smarter technology for all. “Last year at this time, none of us knew how things would turn out for Lenovo,” said Lenovo CEO Yuanqing Yang. “But we did know this: we would support each other in an unpredictable journey ahead; we would fight for the best possible outcome in an uncertain world; and we would use our technology to connect and heal a wounded society.” During the past year the COVID pandemic drove many businesses and consumers around the world to adopt and use technology innovations in new ways,

Coded Agency Celebrates Continued Growth with Rebrand, Internal Promotions and Client Wins14.4.2021 16:00:00 CEST | Press release

Global modern communications company Coded Agency today announces a highly-anticipated, strategic overhaul of its branding and website following steady growth and innovation into new markets and industries. Coded Agency, formerly known as codedpr, was founded in 2015 and quickly grew to become a leading agency of record for a range of lifestyle, fashion, beauty, fitness and wellness brands. In 2020, the agency generated a net income increase of 35%, despite an unprecedented global pandemic. Its upward trajectory continues in 2021 with not only a 65% increase in revenue in Q1 and a 50% increase in clients between Q1 and Q2, but a bold, fresh new look, instrumental employee promotions and expansion into Europe with the agency founder’s relocation to France. The minority-owned, female-founded company renews its namesake as Coded Agency in tandem with a new website and branding designed by Designsake Studio, a San Francisco-based, award-winning and female founded design firm. “Coded Agency

Microsoft Azure Customers Now Able to Acquire beqom with Existing Azure Credit14.4.2021 15:20:00 CEST | Press release

beqom, provider of cloud-based compensation management software, announced that Microsoft has designated beqom as an eligible “Microsoft Transact” application for customers of the Microsoft Azure cloud platform. This means that Azure customers can use their existing Azure budget commitment to fund the purchase of the beqom compensation management solution. “This presents a huge opportunity for Azure customers,” says Francois D’Haegeleer, beqom Head of Business Development. “As an eligible application, if you purchase beqom directly through the Azure Marketplace, Microsoft will contribute 100% of qualifying offer purchases towards your organization’s Azure consumption commitment at each invoice period, including software/IP costs. So you can get beqom’s world-class compensation management platform, used by Global 2000 companies around the world, for no additional budget outlay.” “Our enterprise customers want to streamline their software procurement process,” says Andrew Reid, Microsoft

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer14.4.2021 15:00:00 CEST | Press release

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson’s innovative clinical research infrastructure and the patient-driven drug development capabilities of the Therapeutics Discovery division with Boehringer Ingelheim’s pipeline of innovative cancer medicines and expertise in advancing breakthrough therapies. Under the new agreement, joint research will continue for five additional years. “Our collaboration with MD Anderson strengthens our determination to find solutions for the most difficult-to-treat cancers, and this latest commitment marks an import

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom